ReviewBMC cancer2016
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
Review in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Gastric organoids: A promising model for studying "inflammation-cancer" transition in atrophic gastritis.World journal of clinical oncology · 2025Review
- The role of HSPB1 in modulating ferroptosis in pancreatic cancer via the TP53/SLC7A11/GPX4 axis.Discover oncology · 2025Article
- Review
- Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.Military Medical Research · 2025Review
- Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.Molecular cancer research : MCR · 2023Article
- Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients.International journal of molecular sciences · 2022Article
- Molecular Pathology of Gastric Cancer.Journal of gastric cancer · 2022Review
- Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis.Molecular biology reports · 2022Article
- Systematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer.Middle East journal of digestive diseases · 2022Review
- Volatilomic Signatures of AGS and SNU-1 Gastric Cancer Cell Lines.Molecules (Basel, Switzerland) · 2022Article
- Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma.Journal of cancer research and clinical oncology · 2021Article
- Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma.Journal of oncology · 2021Article
- Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines.PLoS computational biology · 2020Article
- Comprehensive pharmacogenomic characterization of gastric cancer.Genome medicine · 2020Article
- Biased Influences of Low Tumor Purity on Mutation Detection in Cancer.Frontiers in molecular biosciences · 2020Article
- A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer.OncoTargets and therapy · 2020Review
- Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.Molecular medicine reports · 2019Article
- PIK3CA Mutation Analysis in Iranian Patients with Gastric CancerIranian biomedical journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations that activate the PI3K/AKT signaling pathway have been observed in several types of carcinoma and have been associated with patient prognosis. However, the significance of PIK3CA mutations in gastric cancer remains unclear. This retrospective study investigated the relationship between PIK3CA mutations and clinical outcomes in patients with gastric cancer. Additionally, we reviewed the rate of PIK3CA mutations in gastric cancer and the association between PIK3CA mutations and prognosis in human cancers.
methodsThe study included 208 patients with gastric cancer who underwent surgical resection at Kumamoto University Hospital, Japan, between January 2001 and August 2010. Mutations in PIK3CA exons 9 and 20 were quantified by pyrosequencing assays.
resultsPIK3CA mutations were detected in 25 (12 %) of the 208 patients. Ten patients had c.1634A > G (p.E545G), 10 had c.1624G > A (p.E542K), 13 had c.1633G > A (p.E545K), nine had c.3139C > T (p.H1047R), and 1 had c.3140A > G (p.H1047Y) mutations. PIK3CA mutations were not significantly associated with any clinical, epidemiologic, or pathologic characteristic. Kaplan-Meier analysis showed no significant differences in disease-free survival (log rank P = 0.84) and overall survival (log rank P = 0.74) between patients with and without PIK3CA mutations.
conclusionsMutations in PIK3CA did not correlate with prognosis in patients with gastric cancer, providing additional evidence for the lack of relationship between the two.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.